Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.

Psoriasis area and severity index Balinatunfib treatment compared with placebo resulted in a nominally significant improvement in the total PASI score from baseline to Week 2 (17.73% vs. 4.12%, nominal p = 0.005) and Week 4 (35.09% vs. 15.71%, nominal p = 0.009) (Figure 3b,c ; Figure S1B ).

also in 7,732 other papers